Anvisa Registers Five New Semaglutide Pens

Overview

• Anvisa published resolutions on Wednesday registering five injectable semaglutide products—Owozy, Seemasun, Zempneo, Semavy and Orsema—authorized for adults with type 2 diabetes.
• The agency classified each product as a "medicamento novo (novo IFA análogo) por via de desenvolvimento abreviado" and approved prefilled subcutaneous pens with needles based on comparability to the biological reference product.
• The registrations permit commercial sale but give no launch dates, retail prices or full therapeutic labels; manufacturers have said some brands aim to reach pharmacies in the coming months and one company signaled Semavy could arrive soon.
• Market analysts and industry sources say the March patent expiry has unlocked competition from synthetic versions of semaglutide that are likely to expand supply and put downward pressure on prices over time, though immediate impacts are uncertain.
• Wider public access will require separate cost‑effectiveness review and budget approval by Conitec and the Health Ministry, so any inclusion in the Sistema Único de Saúde depends on future policy decisions.